Editas Medicine Plunges 21.34% on In Vivo Shift

On May 21, 2025, Editas Medicine's stock experienced a significant drop of 21.34% in pre-market trading.

Editas Medicine has recently shifted its focus towards in vivo programs, which has been a strategic move to enhance its pipeline and potentially drive future growth. This shift is part of the company's broader strategy to leverage its gene-editing technology in new and innovative ways.

Analysts have provided mixed opinions on the stock. Robert W. Baird recently lowered their target price for Editas Medicine from $8.00 to $4.00, while maintaining an "outperform" rating. This adjustment reflects the market's cautious outlook on the company's near-term prospects, despite its long-term potential.